Palisade Bio, Inc.

PALI

Healthcare Biotechnology

Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00.

Revenue
+19,900.0%
EPS
+91.4%
Free cash flow
−318.4%

Quarter to June 2026, against a year earlier

1.13 0.03 −2.59%
Market cap
$196.9M
P/E
1.8×
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
7.4×
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
— — — — — 3 2 3 5 5
P/E ratio
— — 0.00 — — 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — (13.36) — — (43.69) (49.80) (31.13) (8.18) (12.54)
P/S ratio
— — 20.86 — — 1,085.26 144.63 10.84 70.26 2,246.04
Altman Z″-Score (non-manufacturers)
— — (25.09) — — (110.50) (110.62) (89.30) (48.61) (28.98)
P/FCF ratio
— — 0.00 — — 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — — — (7.05) (0.66) 10.17 (2.88)
P/Operating CF
— — (1.96) — — (9.46) (1.09) (1.70) (7.99) (8.92)
P/B ratio
— — 0.47 — — 0.00 0.43 0.47 2.15 3.21
EV/Sales
— — (26.44) — — 1,116.96 (175.76) 8.11 44.89 1,385.37
EV/EBITDA
— — 0.52 — — 0.00 0.32 0.00 0.00 0.00
EV/FCF
— — 0.61 — — (3.16) 0.37 (0.27) (0.87) (1.43)
Current Ratio
28.95 3.24 5.15 4.89 4.61 0.11 4.61 6.19 8.22 2.85
Net Debt/EBITDA
7.37 0.66 0.94 0.78 0.25 (0.05) 0.58 0.72 0.90 0.83
Debt/Equity
0.00 0.01 0.01 0.01 0.01 (0.16) 0.04 0.00 0.00 0.33
ROE
(24.52%) (153.59%) (103.55%) (143.75%) 576.17% 179.86% (149.62%) (67.72%) (158.04%) (258.77%)
ROA
(23.11%) (115.82%) (82.62%) (100.87%) (342.75%) (214.98%) (117.07%) (45.66%) (85.87%) (112.24%)
ROIC
0.00% 0.00% 0.00% (5,340.01%) 0.00% 0.00% (2,809.80%) (1,966.55%) 0.00% 0.00%
Return on Tangible Assets
(12.95%) (198.84%) (114.55%) (121.56%) (295.31%) 143.74% (187.13%) (88.77%) (141.04%) (152.26%)
Average Days of Receivables
— — 0.00 0.00 0.00 1,595.19 500.10 502.58 521.67 1,432.96
Earnings Yield
— — (324.75%) — — (160.27%) (382.07%) (102.14%) (63.01%) (64.47%)
Free Cash Flow Yield
— — (207.51%) — — (32.60%) (326.34%) (273.47%) (73.50%) (43.19%)
Free Cash Flow per Share
(0.19) (8.61) (24.42) (227.77) (1,191.37) (1,290.27) (14,511.40) (7,614.45) (15,417.01) (157,142.00)
Book value per Share
2.32 5.29 24.81 212.59 593.95 (1,918.65) 10,252.00 5,986.98 9,776.68 113,308.00
Free Cash Flow
(10.85) (12.19) (11.14) (13.37) (14.77) (4.77) (7.26) (7.69) (13.43) (15.71)
EV/EBIT
— — 0.52 — — 0.00 0.31 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026